Institution · ISA Pharmaceuticals (Netherlands)

Most cited papers from ISA Pharmaceuticals (Netherlands)

ISA Pharmaceuticals (Netherlands)

What are the most cited papers from ISA Pharmaceuticals (Netherlands)?

The most cited paper from ISA Pharmaceuticals (Netherlands) is "Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens" (Matthew M. Gubin et al., 2014), with 2,015 citations. Next come "CD4+ T cell help in cancer immunology and immunotherapy" (1,685) and "Therapeutic cancer vaccines" (1,589).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 26 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Matthew M. Gubin et al. · Nature Open access	25 Nov 2014	2,015
2	CD4+ T cell help in cancer immunology and immunotherapy Jannie G. Borst, Tomasz Ahrends, Nikolina Bąbała et al. · Nature reviews. Immunology Review	29 Jul 2018	1,685
3	Therapeutic cancer vaccines Mansi Saxena, Sjoerd H. van der Burg, Cornelis J.M. Melief et al. · Nature reviews. Cancer Review	27 Apr 2021	1,589
4	Therapeutic cancer vaccines Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens et al. · Journal of Clinical Investigation Open access	27 Jul 2015	1,170
5	Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia Gemma G. Kenter, Marij J.P. Welters, A. Rob P.M. Valentijn et al. · New England Journal of Medicine Open access	4 Nov 2009	1,100
6	Vaccines for established cancer: overcoming the challenges posed by immune evasion Sjoerd H. van der Burg, Ramon Arens, FERRY A. OSSENDORP et al. · Nature reviews. Cancer Review	11 Mar 2016	713
7	Cancer Immunotherapy by Dendritic Cells Cornelis J.M. Melief · Immunity Open access	Sep 2008	509
8	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer Erminia Massarelli et al. · JAMA Oncology Open access	29 Sep 2018	493
9	Classification of current anticancer immunotherapies Lorenzo Galluzzi et al. · Oncotarget Open access	18 Dec 2014	475
10	The chromatin remodelling factor Brg‐1 interacts with β‐catenin to promote target gene activation Nick Barker, Adam Hurlstone, Hannah Musisi et al. · The EMBO Journal Open access	3 Sep 2001	454
11	Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses Marij J.P. Welters, Gemma G. Kenter, Peggy J. de Vos van Steenwijk et al. · Proceedings of the National Academy of Sciences Open access	14 Jun 2010	240
12	Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses Marij J.P. Welters, Tetje C. van der Sluis, Hélène van Meir et al. · Science Translational Medicine	13 Apr 2016	215
13	Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T‐cell activation Rodney Alexander Rosalia, Esther D. Quakkelaar, Anke Redeker et al. · European Journal of Immunology Open access	9 Jul 2013	215
14	Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects Marieke F. Fransen, Tetje C. van der Sluis, FERRY A. OSSENDORP et al. · Clinical Cancer Research	21 Jun 2013	201
15	The Human Vaccines Project: A roadmap for cancer vaccine development Pedro J. Romero et al. · Science Translational Medicine	13 Apr 2016	196
16	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Edith M.G. van Esch et al. · Journal of Translational Medicine Open access	4 Apr 2013	192
17	Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer Frank M. Speetjens, Peter J.K. Kuppen, Marij J.P. Welters et al. · Clinical Cancer Research	Feb 2009	184
18	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response Mariëtte I.E. van Poelgeest et al. · Clinical Cancer Research Open access	26 Jan 2016	168
19	Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody Marieke F. Fransen, Marjolein Sluijter, Hans Morreau et al. · Clinical Cancer Research	9 Mar 2011	154
20	Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients Hélène van Meir, Remi A. Nout, Marij J.P. Welters et al. · OncoImmunology Open access	24 Dec 2016	143
21	Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial Ninke Leffers, Annechien J.A. Lambeck, Marloes J.M. Gooden et al. · International Journal of Cancer	28 May 2009	143
22	Consensus nomenclature for CD8+T cell phenotypes in cancer Lionel Apétoh et al. · OncoImmunology Open access	25 Feb 2015	139
23	Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells Elham Beyranvand Nejad, Tetje C. van der Sluis, Suzanne van Duikeren et al. · Cancer Research	28 Aug 2016	138
24	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival Cornelis J.M. Melief et al. · Science Translational Medicine Open access	18 Mar 2020	135
25	Impurities in Oligonucleotide Drug Substances and Drug Products Daniel C. Capaldi, Andy Teasdale, Scott P. Henry et al. · Nucleic Acid Therapeutics	10 Nov 2017	134
26	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance Norma Bloy et al. · Immunological Reviews Review	13 Oct 2017	105
27	Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention Aikaterini Nasi, Stéphanie McArdle, Gustav Gaudernack et al. · Toxicology Reports Open access	2020	98
28	ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response Luana Guimarães de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales et al. · Journal for ImmunoTherapy of Cancer Open access	Feb 2022	97
29	Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates Gijs G. Zom, Selina Khan, Cedrik Michael Britten et al. · Cancer Immunology Research Open access	21 Apr 2014	97
30	Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study Renee Vermeij, Ninke Leffers, Baukje‐Nynke Hoogeboom et al. · International Journal of Cancer Open access	3 Dec 2011	97
31	Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict Therapeutic Efficacy against Tumors Suzanne van Duikeren, Marieke F. Fransen, Anke Redeker et al. · The Journal of Immunology	23 Aug 2012	95
32	A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions Peggy J. de Vos van Steenwijk, Tamara H. Ramwadhdoebé, Margriet J. G. Löwik et al. · Cancer Immunology Immunotherapy Open access	8 Jun 2012	93
33	Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death Tetje C. van der Sluis, Suzanne van Duikeren, Suzanna Huppelschoten et al. · Clinical Cancer Research Open access	12 Dec 2014	91
34	Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy Aurélie Hanoteau, Jared M. Newton, Rosemarie Krupar et al. · Journal for ImmunoTherapy of Cancer Open access	15 Jan 2019	90
35	Inflammasome-Dependent Induction of Adaptive NK Cell Memory Jasper G. van den Boorn, Christopher Jakobs, Christian Hagen et al. · Immunity Open access	Jun 2016	89
36	Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression Tetje C. van der Sluis, Marjolein Sluijter, Suzanne van Duikeren et al. · Cancer Immunology Research Open access	17 Apr 2015	85
37	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer Maartje C.A. Wouters, Fenne L. Komdeur, Hagma H. Workel et al. · Clinical Cancer Research	18 Sep 2015	84
38	Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment Marieke F. Fransen, Ramon Arens, Cornelis J.M. Melief · International Journal of Cancer	2 Aug 2012	84
39	Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis Lionel Blanchet, Agnieszka Smolinska, Amos Attali et al. · BMC Bioinformatics Open access	22 Jun 2011	83
40	CD27-CD70 Costimulation Controls T Cell Immunity during Acute and Persistent Cytomegalovirus Infection Suzanne P. M. Welten, Anke Redeker, Kees L. M. C. Franken et al. · Journal of Virology Open access	11 Apr 2013	79
41	Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia Jane A. O’Halloran et al. · JAMA Open access358 authors	10 Jul 2023	71
42	Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication Gijs G. Zom, Marian M. J. H. P. Willems, Selina Khan et al. · Journal for ImmunoTherapy of Cancer Open access	Dec 2018	71
43	The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study Peggy J. de Vos van Steenwijk, Mariëtte I.E. van Poelgeest, Tamara H. Ramwadhdoebé et al. · Cancer Immunology Immunotherapy Open access	14 Nov 2013	69
44	The viral context instructs the redundancy of costimulatory pathways in driving CD8+ T cell expansion Suzanne P. M. Welten, Anke Redeker, Kees L. M. C. Franken et al. · eLife Open access	11 Aug 2015	62
45	Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial Eliane C.M. Zeestraten, Frank M. Speetjens, Marij J.P. Welters et al. · International Journal of Cancer Open access	5 Sep 2012	61
46	Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer Ninke Leffers, Renee Vermeij, Baukje‐Nynke Hoogeboom et al. · International Journal of Cancer	16 Feb 2011	60
47	Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses Victoria A. Brentville, Rachael L. Metheringham, Ian Daniels et al. · Journal for ImmunoTherapy of Cancer Open access	Jun 2020	55
48	A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection Iris N. Pardieck et al. · Nature Communications Open access	8 Jul 2022	54
49	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer Ramon Arens, Thorbald van Hall, Sjoerd H. van der Burg et al. · Seminars in Immunology	Apr 2013	52
50	Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors Esther D. Quakkelaar et al. · PLoS ONE Open access	15 Feb 2011	51

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.